trial · primary record
Enfortumab Vedotin
Muscle-invasive Bladder Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 240 |
| Primary completion | 2031-04-30 |
| Primary endpoint | Overall clinical complete response (cCR) rate after treatment with enfortumab vedotin in combination with pembrolizumab as assessed by investigator |
| Registry ID | NCT07475806 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:52.195Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07475806
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Enfortumab Vedotin · compound